心室辅助装置支持时长与儿童心脏移植结局的关系
本研究基于儿科心脏移植研究数据库,纳入2000至2018年间1064例VAD后行心脏移植的儿童,比较VAD后30天内与≥30天移植的结局。倾向评分加权后,两组移植后住院时长无差异,但30天内移植组一年生存率更低(校正死亡HR 1.76,95%CI 1.11-2.78,P=0.016)。结论认为较长VAD支持与一年生存获益相关,但因果关系待进一步研究。
要点
- 儿童VAD后30天内心脏移植与一年生存率降低相关。
- 倾向评分加权后两组移植后住院时长无显著差异。
- 较长VAD支持与一年生存获益相关,但因果关系未明。
核心结论
- 儿童心脏移植前较长的VAD支持时长与一年生存获益相关。
- VAD后30天内移植组的一年生存率低于≥30天组(校正死亡HR 1.76,95%CI 1.11-2.78,P=0.016)。
研究设计与样本
- 回顾性队列研究,数据来自儿科心脏移植研究数据库。
- 纳入2000至2018年间VAD后行心脏移植的1064例儿童。
- 采用倾向评分加权(逆概率处理加权),基于年龄、血型、主要心脏诊断、年代、VAD类型和致敏状态计算。
主要发现
- 70%的患者在VAD后≥30天行心脏移植。
- 两组先天性心脏病与心肌病比例无差异(P=0.8),高致敏状态比例无差异(P=0.9)。
- 移植后住院时长两组相似(P=0.11)。
- 30天内移植组一年生存率更低(校正死亡HR 1.76,95%CI 1.11-2.78,P=0.016)。
临床怎么用
- 对于VAD支持的儿童,可考虑适当延长支持时间至30天以上再行心脏移植以改善一年生存。
- 需结合患者复杂度、VAD后并发症等因素个体化决定移植时机。
局限性
- 患者复杂度、VAD后并发症及因果关系问题尚未解决。
- 需使用链接数据库的进一步研究以全面评估VAD后移植最佳时机。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is wide variability in the timing of heart transplant (HTx) after pediatric VAD implant. While some centers wait months before listing for HTx, others accept donor heart offers within days of VAD surgery. We sought to determine if HTx within 30 days versus ≥ 30 after VAD impacts post-HTx outcomes. METHODS: Children on VAD pre-HTx were extracted from the Pediatric Heart Transplant Study database. The primary endpoints were post-HTx length of hospital stay (LOS) and one-year survival. Confounding was addressed by propensity score weighting using inverse probability of treatment. Propensity scores were calculated based on age, blood type, primary cardiac diagnosis, decade, VAD type, and allosensitization status. RESULTS: A total of 1064 children underwent VAD prior to HTx between 2000 to 2018. Most underwent HTx ≥ 30 days post-VAD (70%). Infants made up 22% of both groups. Patients ≥ 12 years old were 42% of the < 30 days group and children 1 to 11 years comprised 47% of the ≥ 30 days group (p < 0.001). There was no difference in the prevalence of congenital heart disease vs. cardiomyopathy (p = 0.8) or high allosensitization status (p = 0.9) between groups. Post-HTx LOS was similar between groups (p = 0.11). One-year survival was lower in the < 30 days group (adjusted mortality HR 1.76, 95% CI 1.11-2.78, p = 0.016). CONCLUSIONS: A longer duration of VAD support prior to HTx is associated with a one-year survival benefit in children, although questions of patient complexity, post-VAD complications and the impact on causality remain. Additional studies using linked databases to understand these factors will be needed to fully assess the optimal timing for post-VAD HTx.
引用
- Butto A, Mao CY, Wright L, et al. Relationship of ventricular assist device support duration with pediatric heart transplant outcomes. J Heart Lung Transplant. 2021. PMID: 34688547. doi:10.1016/j.healun.2021.09.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。